Literature DB >> 8773815

Severe personality disorders. Treatment issues and selection for in-patient psychotherapy.

K Norton1, R D Hinshelwood.   

Abstract

BACKGROUND: Severe personality disorder (SPD) is an imprecise but useful term referring to some notoriously difficult to treat psychiatric patients. Their long-term psychiatric treatment is often unsuccessful, in spite of hospitalisation. The specialist expertise of in-patient psychotherapy units (IPUs) can successfully meet some of SPD patients' needs.
METHOD: Relevant literature on the subject is summarised and integrated with the authors' specialist clinical experience.
RESULTS: Many clinical problems with SPD patients are interpersonal and prevent any effective therapeutic alliance, which is necessary for successful treatment. With in-patients, inconsistencies in treatment delivery and issues surrounding compulsory treatment reinforce patients' mistrust of professionals, compromising accurate diagnosis and an assessment of the need for specialist IPU referral.
CONCLUSIONS: General psychiatric teams are well-placed to plan long-term treatment for SPD patients which may include IPU treatment. Timely referral of selected SPD patients to an IPU maximises a successful outcome, especially if there is appropriate post-discharge collaboration with general psychiatric teams to consolidate gains made.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8773815     DOI: 10.1192/bjp.168.6.723

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  2 in total

1.  Basal Exposure Therapy: A New Approach for Treatment-Resistant Patients with Severe and Composite Mental Disorders.

Authors:  Didrik Heggdal; Roar Fosse; Jan Hammer
Journal:  Front Psychiatry       Date:  2016-12-19       Impact factor: 4.157

2.  Inpatient management of borderline personality disorder at Helen Joseph Hospital, Johannesburg.

Authors:  Laila Paruk; Albert B R Janse van Rensburg
Journal:  S Afr J Psychiatr       Date:  2016-06-17       Impact factor: 1.550

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.